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Introduction
============

The bacterial ecology of the oropharynx of patients in intensive care units undergoes substantial alteration.[@ref1] [@ref2] This can lead to ventilator associated pneumonia, other infections, and death. In an attempt to reduce the incidence of these complications, approaches to decontamination include various forms of antibiotic prophylaxis or the use of topical oropharyngeal antiseptic agents (mostly chlorhexidine). Antibiotic prophylaxis can include any combination of oropharyngeal, intragastric, and intravenous antibiotics. There are, however, two main approaches: selective digestive decontamination (SDD) and selective oropharyngeal decontamination (SOD).

Selective digestive decontamination consists of oropharyngeal and gastric application of non-absorbable antibiotics---often polymyxin, tobramycin, and amphotericin---along with a short course of an intravenous antibiotic, often cefotaxime. Oropharyngeal antibiotics are applied as a paste, usually four times a day, during routine mouth care; gastric antibiotics are administered as a suspension through a nasogastric tube. Surveillance bacteriology, often twice a week, can be used to assess efficacy of decontamination. The choice of therapeutic antibiotics aims to minimise interference with the native anaerobic flora by avoiding agents such as broad spectrum penicillins. Selective oropharyngeal decontamination is the application of the topical antibiotic paste to the oropharynx only, without enteral or empirical intravenous antibiotics.[@ref3] Chlorhexidine is applied as part of routine mouth care in gel or liquid form up to four times a day.

There has been considerable debate about the role of antibiotic prophylaxis,[@ref4] [@ref5] [@ref6] and antibiotic prophylaxis is seldom used in the United Kingdom.[@ref7] Topical oropharyngeal antiseptic agents (usually chlorhexidine) have, by contrast, gained more widespread acceptance and appear as a key recommendation in UK,[@ref8] European,[@ref9] and US[@ref10] guidelines. Nevertheless, interest in this topic remains current.[@ref11]

Numerous meta-analyses of antibiotic and antiseptic prophylaxis have been published over the years. A 2009 Cochrane review suggested that mortality was significantly reduced by selective digestive decontamination.[@ref12] Another review and meta-analysis from 2007 concluded that mortality was unaffected by oropharyngeal antibiotic or antiseptic decontamination.[@ref13] More recent meta-analyses of oropharyngeal antiseptics (mostly chlorhexidine) have focused on the incidence of ventilator associated pneumonia,[@ref14] [@ref15] [@ref16] although some meta-analyses of oropharyngeal chlorhexidine have reported a trend towards increased mortality.[@ref15] [@ref17]

Despite the favourable results seen in meta-analyses of selective digestive decontamination, interpretation should be tempered by the use of standard care as a control group in the contributory trials. Given the likely widespread use of chlorhexidine, any putative mortality advantage of selective digestive decontamination or selective oropharyngeal decontamination needs to be re-defined. As we are not aware of any clinical trials directly comparing selective digestive decontamination or selective oropharyngeal decontamination with topical chlorhexidine, we aimed to use a network meta-analysis to compare the effect of these interventions on mortality. This required us to undertake an updated systematic review looking for randomised controlled trials reporting the effect of selective digestive decontamination, selective oropharyngeal decontamination, and topical chlorhexidine on mortality in adult patients in general intensive care units. We also wanted to update conventional intervention-control meta-analyses of the three interventions in light of any recent studies. We elected not to study the outcome of ventilator associated pneumonia as we consider mortality to be the most robust outcome, and this was the focus of recent large trials of selective digestive decontamination.[@ref18] [@ref19]

Method
======

Sources of data
---------------

We searched Medline, Embase, and the Cochrane Register of Clinical Trials from 1984 until December 2012. We constructed a search strategy around patients in intensive care, intervention with antibiotic or antiseptic prophylaxis, and the outcome of death. The Medline search strategy is shown in the appendix and similar strategies were applied to the Embase and CENTRAL databases. There were no language restrictions. We screened results of the database searches by title and abstract. Given the extent of previous systematic reviews, we reviewed recent meta-analyses (published from 2005 to 2012[@ref12] [@ref13] [@ref14] [@ref15] [@ref16] [@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28]) for included studies that were missed in database searches. Congress abstracts were searched from 2005 to 2012 for the European Society for Intensive Care Medicine, Society for Critical Care Medicine, Symposium of Intensive Care and Emergency Medicine, and Chest. The contents pages of the journals Intensive Care Medicine, Critical Care Medicine, Chest, Critical Care, American Journal of Respiratory and Critical Care Medicine, Journal of Hospital Infection, and Infection Control and Hospital Epidemiology were reviewed from January 2005 to December 2012. The website [controlled-trials.com](controlled-trials.com) was used to search registers of clinical trials. We did not search for unpublished studies or contact experts in the field. We wrote to authors if indicated.

Inclusion criteria
------------------

We sought prospective randomised controlled clinical trials in adult patients in general intensive care units. We did not stipulate placebo control or blinding. We defined "selective digestive decontamination" as the application of a combination of poorly absorbable antibiotics to the oropharynx and the stomach combined with empirical intravenous antibiotics. "Selective oropharyngeal decontamination" was defined as the application of a combination of poorly absorbable antibiotics only to the oropharynx. "Chlorhexidine" was defined as the application of any concentration of chlorhexidine in any formulation to the oropharynx. The control group must have received only standard care or placebo.

Exclusion criteria
------------------

We excluded trials that recruited only children, populations not in intensive care, and specialised populations (such as cardiac surgery and liver transplantation). We excluded trials in which both groups received active topical drugs or in which the control group received empirical intravenous antibiotics. Finally we excluded studies combining oropharyngeal and gastric application of antibiotics or gastric or subglottic application alone from the selective oropharyngeal decontamination meta-analysis.

Quality assessment
------------------

We summarised potential biases with the Cochrane risk of bias tool. There are six domains: sequence generation; allocation concealment; blinding; if the outcomes reported were prespecified; completeness of outcome data; and other potential sources of bias. We have also presented information on each study to show potential issues of clinical heterogeneity.

Data extraction
---------------

Results were extracted from the included studies, from our own communication with authors, or from previous meta-analyses if intention to treat data had been verified with the original study authors.

Consensus
---------

Two authors (RP, JG) independently performed study inclusion, data extraction, and quality assessment. Disagreement at the stage of abstract screening was resolved by inclusion of the full paper for review. Disagreement at later stages was resolved by discussion. Our approaches to studies with a three arm design are presented in the appendix.

Statistical methods
-------------------

### Intervention-control pairwise meta-analyses

We summarised data from each study with log odds ratios and 95% confidence intervals. This approach was used to allow the inclusion of the study by de Smet and colleagues,[@ref19] which used a cluster randomised crossover design analysed by the authors using multilevel logistic regression. We used the log odds ratios and standard errors that de Smet and colleagues[@ref19] reported and calculated the log odds ratios and standard errors for the remaining studies based on the reported events and sample sizes. Forest plots are included as a visual aid to interpret the direct evidence. Pairwise meta-analyses were done in Review Manager (RevMan), version 5.0 (Cochrane Collaboration, 2008).

### Network meta-analysis

We used a generalised linear modelling framework as outlined in Dias and colleagues[@ref29] to do a network meta-analysis. A "trial level" approach was used, in which the data modelled were the summary log odds ratios and standard errors for each trial as outlined above. All model parameters were estimated within a Bayesian framework with WinBUGS software.[@ref30] We present estimates of treatment effects as odds ratios and 95% central credible intervals (CrI). The credible interval shows the degree of uncertainty around estimated treatment effects.

We also calculated individual estimates of the probability of death for each intervention. These estimates were derived from the model by using a baseline distribution for the probability of death in the control group, in combination with the odds ratio between each intervention and control. Vague prior distributions were used on the necessary parameters: the log odds ratios of intervention procedures versus control and the standard deviation between studies. A run-in period of 50 000 iterations was adequate to achieve convergence, and a further 100 000 samples were taken.

Results
=======

Systematic review
-----------------

We identified 29 studies as suitable for inclusion[@ref18] [@ref19] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] (figure 1[](#fig1){ref-type="fig"}). Tables 1-3[](#tbl1){ref-type="table"} [](#tbl2){ref-type="table"} [](#tbl3){ref-type="table"} show the components of the Cochrane risk of bias tool for each intervention. Tables 4-6[](#tbl2){ref-type="table"} [](#tbl4){ref-type="table"} [](#tbl5){ref-type="table"} [](#tbl6){ref-type="table"} show areas of potential clinical heterogeneity between the studies and our data source. Raw outcome data are presented in table A in the appendix.

![Fig 1 Inclusion of studies in analysis of effect of selective digestive decontamination (SDD), selective oropharyngeal decontamination (SOD), and topical oropharyngeal chlorhexidine for prevention of death in adults in intensive care](prir014059.f1_default){#fig1}

###### 

 Methodological aspects of included trials on effect of selective digestive decontamination (SDD) for prevention of death in adults in intensive care

                       Adequate sequence generation   Allocation concealment   Blinding   Outcome prespecified                                       Incomplete outcome data addressed                                                     Other bias
  -------------------- ------------------------------ ------------------------ ---------- ---------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------
  Aerdts^31^           Yes                            Yes\*^12^                No         Per protocol mortality reported in published paper         Intention to treat analysis possible from previous communication with authors\*^12^   ---
  Blair^32^            Unclear                        Yes\*^12^                No         Mortality reported                                         Intention to treat analysis possible from data provided                               ---
  Boland^33^           Yes\*^12^                      Unclear                  Yes        Mortality not reported                                     Intention to treat analysis possible from previous communication with authors\*^12^   Published only in abstract form
  Cockerill^34^        Yes                            Yes                      No         Mortality reported                                         Intention to treat analysis performed                                                 ---
  De Jonge^18^         Yes                            Yes                      No         Study powered for mortality. Mortality reported            Intention to treat analysis performed                                                 Active and control ICUs, potential for other differences in care
  De Smet^19^          Yes                            Yes                      No         Study powered for mortality. Mortality reported            Adjusted 28 day mortality used: 1979/1990 in standard care; 2018/2045 in SDD          Statistical correction of baseline differences discussed
  Jacobs^35^           Unclear                        Yes                      No         Mortality reported                                         Intention to treat analysis possible from data provided                               Uncorrected relevant baseline imbalance
  Kreuger^36^          Yes                            Yes                      Yes        Mortality reported                                         Intention to treat analysis performed                                                 ---
  Palomar^37^          Yes                            Yes\*^12^                No         Per protocol mortality reported in published paper         Intention to treat analysis possible from previous communication with authors\*^12^   Uncorrected relevant baseline imbalance
  Rocha^38^            Yes                            Yes                      Yes        Per protocol mortality reported in published paper         Intention to treat analysis possible from previous communication with authors\*^12^   Placebo group had high mortality for the unit norm
  Sanchez-Garcia^39^   Yes                            Yes                      Yes        Mortality defined secondary endpoint. Mortality reported   Intention to treat analysis performed                                                 ---
  Stoutenbeek^40^      Yes                            Yes                      No         Mortality primary endpoint. Mortality reported             401/405 analysed                                                                      Minor baseline imbalances.
  Ulrich^41^           Unclear                        Yes\*^12^                No         Mortality reported (incomplete)                            Intention to treat analysis possible from previous communication with authors\*^12^   ---
  Verwaest^42^         Yes                            Yes                      No         Mortality a defined endpoint. Mortality reported           Intention to treat analysis possible from previous communication with authors\*^12^   ---
  Winter^43^           Yes                            Yes                      No         Mortality reported                                         Intention to treat analysis performed                                                 ---

\*Information taken from Cochrane^12^ or Chan^13^ after their correspondence with authors.

###### 

 Methodological aspects of included trials on effect of selective oropharyngeal decontamination (SOD) for prevention of death in adults in intensive care

                 Adequate sequence generation   Allocation concealment   Blinding   Outcome prespecified                                       Incomplete outcome data addressed                                                     Other bias
  -------------- ------------------------------ ------------------------ ---------- ---------------------------------------------------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------
  Bergmans^44^   Unclear                        Yes                      Yes        Mortality defined secondary endpoint. Mortality reported   226/245 patients analysed                                                             ---
  De Smet^19^    Yes                            Yes                      No         Study powered for mortality. Mortality reported            Adjusted 28 day mortality used: 1979/1990 in standard care; 1886/1904 in SOD          Statistical correction of baseline differences discussed
  Pugin^45^      Unclear                        Yes\*^12^                Yes        Per protocol mortality reported in published paper         Intention to treat analysis possible from previous communication with authors\*^12^   ---
  Rios^46^       Unclear                        Unclear                  Yes        Per protocol mortality reported in published paper         96/116 patients analysed                                                              Published only in abstract form

\*Information taken from Cochrane^12^ or Chan^13^ after their correspondence with authors.

###### 

 Methodological aspects of included trials on effect of topical oropharyngeal chlorhexidine for prevention of death in adults in intensive care

                              Adequate sequence generation   Allocation concealment   Blinding   Outcome prespecified                                                            Incomplete outcome data addressed                                                     Other bias
  --------------------------- ------------------------------ ------------------------ ---------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ---------------------------------
  Bellissimo- Rodrigues^47^   Unclear                        Yes                      Yes        Mortality a defined secondary endpoint. Mortality reported                      194/200 patients analysed. Reasons for exclusions discussed                           ---
  Berry^48^                   Yes                            Yes                      No         Mortality not reported                                                          Intention to treat data obtained from author                                          ---
  Cabov^49^                   Yes                            Unclear                  Yes        Mortality reported                                                              Intention to treat analysis performed                                                 ---
  Fourrier 2000^50^           Yes                            Unclear                  Partial    Mortality reported                                                              Intention to treat analysis performed                                                 ---
  Fourrier 2005^51^           Unclear                        Yes                      Yes        Mortality a defined secondary endpoint. Mortality reported                      Intention to treat analysis performed                                                 Censored at 28 days
  Koeman^52^                  Yes                            Unclear                  Yes        Mortality defined secondary endpoint. Mortality reported as hazard ratio only   Intention to treat analysis possible from previous communication with authors\*^13^   ---
  MacNaughton^53^             Unclear                        Unclear                  Yes        Mortality not reported                                                          Unclear                                                                               Published only in abstract form
  Munro^54^                   Yes                            Unclear                  No         Mortality reported (subgroup of total population)                               Intention to treat data obtained from author                                          Stopped intervention at day 7
  Panchabhai^55^              Unclear                        Unclear                  No         Mortality a defined secondary endpoint. Per protocol mortality reported         471/512 patients analysed. Reasons for exclusions discussed                           ---
  Scannapieco^56^             Yes                            Yes                      Yes        Mortality a defined secondary endpoint Mortality reported                       Intention to treat data obtained from author                                          Censored at 21 days
  Tantipong^57^               Unclear                        Unclear                  No         Mortality reported                                                              Intention to treat analysis performed                                                 ---

\*Information taken from Cochrane^12^ or Chan^13^ after their correspondence with authors.

###### 

 Other aspects of included trials on effect of selective digestive decontamination (SDD) for prevention of death in adults in intensive care

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                       Topical drugs                                       Intravenous drugs                     Control group                                                                                                   Accrual period                                Population                                Place study undertaken                                Projected ventilator or ICU time                            Timing of outcome
  -------------------- --------------------------------------------------- ------------------------------------- --------------------------------------------------------------------------------------------------------------- --------------------------------------------- ----------------------------------------- ----------------------------------------------------- ----------------------------------------------------------- --------------------------------------------------------
  Aerdts^31^           Polymyxin, Norfloxacin, Amphotericin                Cefotaxime 500 mg TDS/5 days          No antibiotic prophylaxis. 2 control groups: either penicillin or cephalosporin based therapeutic antibiotics   May 1986-Sep 1987                             Mixed                                     Nijmegen, Netherlands                                 \>5 days of mechanical ventilation                          ICU discharge

  Blair^32^            Polymyxin, Tobramycin, Amphotericin                 Cefotaxime 50 mg/kg/day/4 days        Standard antibiotic therapy                                                                                     Sep1988-Jan1990                               Mixed, 93% ventilated                     Belfast, UK                                           \>48 hr in ICU                                              ICU discharge

  Boland^33^           Polymyxin, Tobramycin, Nystatin                     Cefotaxime/3 days                     Placebo                                                                                                         Not specified                                 Multiple trauma, all ventilated           Charleston, WV, US                                    \>5 days intubated                                          ICU discharge

  Cockerill^34^        Polymyxin, Gentamicin, Nystatin                     Cefotaxime 1 g TDS/3 days             No antibiotic prophylaxis                                                                                       1986-1989                                     Mixed, uninfected, 85% ventilated         Rochester, MN, US                                     \>3 days in ICU                                             ICU discharge

  De Jonge^18^         Polymyxin, Tobramycin, Amphotericin                 Cefotaxime 1 g QDS/4 days             No antibiotic prophylaxis                                                                                       Sep 1999- Dec 2001                            Mixed, 85% ventilated                     Amsterdam, Netherlands                                \>48 hr of mechanical ventilation or 3 days in ICU          ICU discharge

  De Smet^19^          Polymyxin, Tobramycin, Amphotericin                 Cefotaxime 1 g QDS/4 days, or none.   No antibiotic prophylaxis                                                                                       May 2004-July 2006                            Mixed, 90% ventilated                     Multiple sites (13), Netherlands                      \>48 hr of mechanical ventilation or 3 days in ICU          28 days

  Jacobs^35^           Polymyxin, Tobramycin, Amphotericin                 Cefotaxime 50 mg/kg/day/4 days        Normal management. Low gastric pH encouraged.                                                                   July 1989-Aug 1990                            Mixed, 50% neurological, all ventilated   Cardiff, UK                                           \>3 days in ICU                                             Unclear

  Kreuger^36^\         Polymyxin, Gentamicin (Vancomycin & Amphotericin)   Ciprofloxacin 400 mg BD/4 days        Placebo                                                                                                         2.5 yr, dates not given (published 2002)      90% surgical and trauma                   2 sites, Tübingen, Germany                            \>48 hr in ICU                                              ICU discharge

  Palomar^37^          Polymyxin, Tobramycin, Amphotericin                 Cefotaxime 1 g TDS/4 days             No antibiotic prophylaxis                                                                                       July 1989- July 1991                          Mixed, uninfected                         Multiple sites (10), Catalonia, Spain                 \>4 days of mechanical ventilation                          ICU discharge

  Rocha^38^            Polymyxin, Tobramycin, Amphotericin                 Cefotaxime 2 g TDS/4 days             Placebo                                                                                                         14 months, dates not given (published 1992)   80% trauma, uninfected                    La Coruna, Spain                                      \>3 days of mechanical ventilation and \> 5 days ICU stay   ICU discharge

  Sanchez-Garcia^39^   Polymyxin, Gentamicin, Amphotericin                 Ceftriaxone 2 g OD/3 days             Placebo                                                                                                         Not stated (published 1998)                   Mixed, 70% medical                        Multiple sites (5), Madrid, Spain                     \>48 hr of intubation                                       ICU discharge

  Stoutenbeek^40^      Polymyxin, Tobramycin, Amphotericin                 Cefotaxime 1 g QDS/4 days             Standard antibiotic therapy for each centre                                                                     Oct 1991-June 1994                            Blunt multi trauma, all ventilated        Multiple sites (17): Europe, Australia, New Zealand   Not a criterion                                             ICU discharge or up to 2 weeks following ICU discharge

  Ulrich^41^           Polymyxin, Norfloxacin, Amphotericin                Trimethoprim 500 mg OD/3 days         Appropriate perioperative prophylaxis                                                                           Oct 1986-Sep 1987                             Mixed                                     Hague, Netherlands                                    \>5 days in ICU                                             ICU discharge

  Verwaest^42^         Ofloxacin, Amphotericin                             Ofloxacin 200 mg OD/4 days            Conventional antibiotic policy                                                                                  19 months, dates not given (published 1997)   75% surgical, third cardiac               Leuven, Belgium                                       \>48 hr of mechanical ventilation                           ICU discharge

  Winter^43^           Polymyxin, Tobramycin, Amphotericin                 Ceftazidime 50 mg/kg/day/3 days       Nothing specified                                                                                               22 months, dates not given (published 1992)   Mixed                                     Bristol, UK                                           \>48 hr in ICU                                              Hospital discharge
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

 Other aspects of included trials on effect of selective oropharyngeal decontamination (SOD) for prevention of death in adults in intensive care

                 Topical drugs                                Control group   Accrual period      Population                     Place study undertaken            Projected ventilator or ICU time     Timing of outcome
  -------------- -------------------------------------------- --------------- ------------------- ------------------------------ --------------------------------- ------------------------------------ --------------------
  Bergmans^44^   Gentamicin, Polymyxin, Vancomycin / QDS      Placebo         Sep 1994-Dec 1996   Mixed ICU, all ventilated      Multiple sites (3), Netherlands   \>48 hr of mechanical ventilation    ICU discharge
  Pugin^45^      Polymyxin, Neomycin, Vancomycin / 4 hourly   Placebo         Apr-Nov 1989        Surgical ICU, all ventilated   Geneva, Switzerland               \>48 hr of intubation                Hospital discharge
  Rios^46^       Polymyxin, Gentamicin / TDS                  Placebo         Uncertain           Uncertain                      Buenos Aires, Argentina           \>4 days of mechanical ventilation   Unclear

###### 

 Other aspects of included trials on effect of oropharyngeal chlorhexidine for prevention of death in adults in intensive care

                              Chlorhexidine             Control group                               Accrual period                           Population                                                         Place study undertaken              Projected ventilator or ICU time                       Timing of outcome
  --------------------------- ------------------------- ------------------------------------------- ---------------------------------------- ------------------------------------------------------------------ ----------------------------------- ------------------------------------------------------ --------------------
  Bellissimo- Rodrigues^47^   0.12% solution TDS        Placebo                                     Mar 2006-Feb 2008                        Mixed ICU, 69% ventilated                                          Sao Paulo, Brazil                   \>48 hr in ICU                                         ICU discharge
  Berry^48^                   0.2% solution BD          Either water or bicarbonate mouth rinses    Uncertain, 15 month recruitment period   Mixed ICU, 100% ventilated                                         Sydney, Australia                   Not specified                                          ICU discharge
  Cabov^49^                   0.2% gel TDS              Placebo                                     Mar 2008- Dec 2008                       Surgical ICU, 100% ventilated                                      Zagreb, Croatia                     \>3 days in ICU and requiring mechanical ventilation   ICU discharge
  Fourrier 2000^50^           0.2% gel TDS              Bicarbonate mouth rinses                    June 1997- July 1998                     Mixed ICU, 100% ventilated                                         Lille, France                       \>5 days in ICU and requiring mechanical ventilation   Unclear
  Fourrier 2005^51^           0.2% gel TDS              Placebo                                     Jan 2001-Sep 2002                        Mixed ICU, 100% ventilated                                         Multiple sites (6), Lille, France   \>5 days in ICU and requiring mechanical ventilation   28 days
  Koeman^52^                  2% gel QDS                Placebo                                     Feb 2001 - Mar 2003                      Mixed ICU, 100% ventilated                                         Multiple sites (7), Netherlands     \>48 hr of mechanical ventilation                      ICU discharge
  MacNaughton^53^             0.2% BD                   Placebo                                     Uncertain                                Mixed ICU, 100% ventilated                                         Plymouth, UK                        \>48 hr of mechanical ventilation                      ICU discharge
  Munro^54^                   0.12% solution BD         Either usual care or toothbrushing groups   Uncertain                                Mixed ICU, 100% ventilated                                         Richmond, VA, US                    Not specified.                                         Hospital discharge
  Panchabhai^55^              0.12% solution BD         0.01% potassium permanganate                Uncertain, 8 month recruitment period    Mediconeuro ICU, 171/471 ventilated                                Mumbai, India                       \> 48 hr in ICU                                        ICU discharge
  Scannapieco^56^             0.12% solution OD or BD   Placebo                                     Mar 2004-Nov 2007                        Trauma ICU, 100% ventilated                                        Buffalo, NY, US                     Not specified                                          21 days
  Tantipong^57^               2% solution QDS           Normal saline                               Jan 2006-Mar 2007                        Surgical or medical ICU or general medical ward, 100% ventilated   Bangkok, Thailand                   Not specified                                          Unclear

Intervention-control pairwise meta-analyses
-------------------------------------------

The random effects estimate for selective digestive decontamination compared with control on mortality gave an odds ratio of 0.73 (95% confidence interval 0.64 to 0.84), favouring selective digestive decontamination (fig 2[](#fig2){ref-type="fig"}). For selective oropharyngeal decontamination and chlorhexidine the odds ratios were 0.85 (0.74 to 0.97) and 1.25 (1.05 to 1.50), respectively (figs 3[](#fig3){ref-type="fig"} and 4[](#fig4){ref-type="fig"}). The only direct evidence for selective digestive decontamination compared with selective oropharyngeal decontamination was from a single trial,[@ref19] which gave an odds ratio of 0.97 (0.79 to 1.18). Results are summarised in table 7[](#tbl7){ref-type="table"}.

![Fig 2 Forest plot of intervention-control pairwise meta-analysis of selective digestive decontamination v control in adult patients in intensive care](prir014059.f2_default){#fig2}

![Fig 3 Forest plot of intervention-control pairwise meta-analysis of selective oropharyngeal decontamination v control in adult patients in intensive care](prir014059.f3_default){#fig3}

![Fig 4 Forest plot of intervention-control pairwise meta-analysis of chlorhexidine v control in adult patients in intensive care](prir014059.f4_default){#fig4}

###### 

 Results of meta-analyses of effect of selective digestive decontamination (SDD), selective oropharyngeal decontamination (SOD), and topical oropharyngeal chlorhexidine for prevention of death in adults in intensive care

  Comparison                  OR (95% CI/CrI)       
  --------------------------- --------------------- ---------------------
  Chlorhexidine *v* control   1.25 (1.05 to 1.50)   1.23 (0.99 to 1.49)
  SDD *v* control             0.73 (0.64 to 0.84)   0.74 (0.63 to 0.86)
  SOD *v* control             0.85 (0.74 to 0.97)   0.82 (0.62 to 1.02)
  SDD *v* chlorhexidine       ---                   0.61 (0.47 to 0.78)
  SOD *v* chlorhexidine       ---                   0.67 (0.48 to 0.91)
  SDD *v* SOD                 0.97 (0.79 to 1.18)   0.91 (0.70 to 1.19)

Results of network meta-analyses
--------------------------------

The odds ratios (95% credible interval) for mortality for active treatment compared with control were 0.74 (0.63 to 0.86) for selective digestive decontamination, 0.82 (0.62 to 1.02) for selective oropharyngeal decontamination, and 1.23 (0.99 to 1.49) for chlorhexidine (table 7[](#tbl7){ref-type="table"}). For the comparison between treatments, the odds ratios were 0.61 (0.47 to 0.78) for selective digestive decontamination compared with chlorhexidine and 0.67 (0.48 to 0.91) for selective oropharyngeal decontamination compared with chlorhexidine. There was uncertainty around the difference between selective digestive decontamination and selective oropharyngeal decontamination. Table 8 shows probabilistic ranking of interventions[](#tbl8){ref-type="table"}.

###### 

 Probabilistic ranking of interventions and estimated probability of death in adults in intensive care treated with selective digestive decontamination (SDD), selective oropharyngeal decontamination (SOD), or topical oropharyngeal chlorhexidine

  Intervention    Rank   Estimated probability of death   Probability of intervention being best
  --------------- ------ -------------------------------- ----------------------------------------
  SDD             1      0.213                            0.740
  SOD             2      0.228                            0.260
  Control         3      0.266                            \<0.001
  Chlorhexidine   4      0.305                            \<0.001

Discussion
==========

Using a network meta-analysis to compare each intervention indirectly, we conclude that both selective digestive decontamination and selective oropharyngeal decontamination are superior to chlorhexidine in preventing death in adults in intensive care. This suggests that the mortality advantage of both these options remains relevant even if chlorhexidine is widely used. Any difference between these treatments is inconclusive, with considerable uncertainty.

Our finding that selective digestive decontamination is associated with a survival benefit in adults in general intensive care units agrees with the conclusions of earlier meta-analyses, but we have now integrated the results of a large cluster randomised crossover trial. Results were similar with both conventional and Bayesian analysis. Selective oropharyngeal decontamination was associated with a reduction in death in the meta-analysis of direct evidence. Contrary to our expectations, use of oropharyngeal chlorhexidine was associated with an increase in mortality in adults in general intensive care units.

Limitations of our study
------------------------

Despite our inclusion criteria, our results are limited by the inevitable heterogeneity among the included studies (tables 4-6[](#tbl4){ref-type="table"} [](#tbl5){ref-type="table"} [](#tbl6){ref-type="table"}), with some common themes.

Within the chlorhexidine studies, the concentration of chlorhexidine used varied from 0.12% to 2% and the number of daily applications varied from one to four. In addition, the duration of the course of treatment varied and in one study was limited to seven days.[@ref54]

Within the selective digestive decontamination studies, most were not blinded and were not placebo controlled. Of those that were blinded,[@ref36] [@ref38] [@ref39] only one explicitly reported concealment of microbial culture results.[@ref39] We consider that this lack of blinding would have had the least influence on the robust outcome of mortality. We could not find any suggestion of differential treatment of patients in the active treatment group over control patients, although we cannot entirely exclude it. Infected patients were excluded in three studies.[@ref34] [@ref37] [@ref38] There was some variability in the exact antimicrobial regimen used; the influence of different regimens has previously been discussed[@ref58] and has been shown to influence at least infective outcomes.[@ref42] Two studies differed slightly in their protocols by locally decontaminating blind bowel loops and tracheal stomas and by treating persistent tracheal colonisation with aerosolised polymyxin or amphotericin.[@ref18] [@ref19]

For each included selective digestive decontamination study, the total proportion of patients in the intensive care unit that were included in the trial was generally unclear. The only included study to use a whole unit approach[@ref18] showed a mortality benefit that was greater than that seen in meta-analyses (although problems with this study have been highlighted.)[@ref59] [@ref60] Thus the generalisability of these studies to a unit where selective digestive decontamination or selective oropharyngeal decontamination is applied to every patient needs to be considered as selective digestive decontamination can alter the ecology of the unit.[@ref32] [@ref61] [@ref62]

When we considered all studies, there was variability in the minimum predicted ventilator time or stay in the intensive care unit. The proportion of ventilated patients varied from 36% in one study[@ref55] to 100%.

A network meta-analysis rests on the comparability of a common control group. Given the temporal variation (year of publication ranging from 1989 to 2011) and wide geographic representation (tables 4-6[](#tbl4){ref-type="table"} [](#tbl5){ref-type="table"} [](#tbl6){ref-type="table"}), there is probably variation among the control groups of the included studies. Control group treatments were generally poorly detailed, although we have identified some variation---for example, the use of topical bicarbonate[@ref48] [@ref50] or potassium permanganate.[@ref55] When other control group treatments were described, they were generally limited to the use of gastric ulcer protection or non-pharmacological mouth care strategies.

When we considered the effect of chlorhexidine on mortality, mortality was not the primary outcome of any of the included studies and a significant increase in mortality was seen in only one[@ref54] of the 11 studies. Additionally, we are aware of one further study[@ref63] of the use of oropharyngeal chlorhexidine that could have fulfilled our inclusion criteria, but we were unable to include it as we could not obtain mortality data.

Implications of this study
--------------------------

In adult patients in general intensive care units, and within the limits of a network meta-analysis, we propose that both selective digestive decontamination and selective oropharyngeal decontamination are superior to chlorhexidine. In keeping with results of earlier studies, we have shown that selective digestive decontamination is associated with reduced mortality. We raise the possibility that oropharyngeal chlorhexidine might be associated with an increase in mortality, and we therefore question whether oropharyngeal chlorhexidine is "safe and effective."[@ref11] Certainly our findings are at odds with the apparently favourable effects of chlorhexidine on the incidence of ventilator associated pneumonia,[@ref14] [@ref15] [@ref16] although the attributable mortality of this might be small.[@ref64] We consider that the role of oropharyngeal chlorhexidine in these patients needs to be explored further. We agree that it would be appropriate to undertake additional prospective studies comparing selective digestive decontamination, selective oropharyngeal decontamination, and chlorhexidine[@ref11] [@ref65] after barriers to implementation or any further trials have been explored.[@ref66]

### What is already known on this topic

1.  Numerous studies and meta-analyses have shown a mortality benefit with use of selective digestive decontamination in patients in intensive care

2.  Meta-analyses have shown that oropharyngeal chlorhexidine is associated with a reduced incidence of ventilator associated pneumonia, without a measurable effect on mortality

### What this paper adds

1.  This network meta-analysis showed that both selective digestive decontamination and selective oropharyngeal decontamination confer a mortality benefit when compared with chlorhexidine in adult patients in general intensive care units

2.  In these patients, selective digestive decontamination was associated with reduced mortality, as in earlier meta-analyses, but the current analysis integrated a large recent cluster crossover study

3.  It is possible that use of chlorhexidine is associated with an increase in mortality

We thank Amanda Wright for librarian services, Silvia Hernandez for translation services and obtaining additional information from a study author, and Artur Pryn. We also thank Angela Berry, Cindy Munro, and Frank Scannapieco for providing additional data; and Fernando Bellissimo Rodrigues, Michele Darby, Mirelle Koeman, Mercedes Palomar, and Miguel Sanchez Garcia for providing additional information.

Contributors: RP and GM designed the study. RP and JG did the literature search, reviewed studies for inclusion, assessed the included studies, and extracted data. GM analysed the data. All three authors wrote, reviewed, and then approved the manuscript. RP is guarantor.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing interests: All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/coi_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Not required.

Data sharing: No additional data available.

Transparency: The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Cite this as: BMJ 2014;348:g2197
